Tania Tabone1, Hazem J Abuhusain2, Anna K Nowak3, Wendy N Erber1, Kerrie L McDonald2. 1. Translational Cancer Pathology Laboratory, School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia, Australia. 2. Cure Brain Cancer Neuro-oncology Group, Prince of Wales Clinical School, UNSW Australia. 3. Department of Medical Oncology, School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Abstract
UNLABELLED: Glioblastoma (GBM) is a highly aggressive malignancy and the most effective treatment regime has a high relapse rate. Increasingly, the development of therapies involves defining drug-diagnostic combinations where the presence of a molecular target or marker identifies patients who are most likely to respond to a specific therapy. Trials in other solid cancers have demonstrated clear utility in the incorporation of biomarkers to stratify patients to targeted treatment, however, there are no mutations that are currently used to inform treatment options for GBM. AIMS: We piloted the use of high-throughput next-generation sequencing technology to identify genetic mutations in 44 GBM specimens that may be amenable to current or future targeted therapeutic strategies. METHOD: Somatic mutation profiling was performed using the AmpliSeq Cancer Hotspot Panel v2 and semiconductor sequencing technology. RESULTS: A total of 66 mutations were detected in 35/44 (80%) patients. The number of mutations per tumour ranged from 0 to 4 (average per tumour=1.5). The most frequent mutations were in TP53 (n=12), PTEN (n=9), EGFR (n=8) and PIK3CA (n=5). Clinically actionable somatic mutations were detected in 24/35 (69%) patients. CONCLUSIONS: This study demonstrates that the use of an 'off-the-shelf' oncogene primer panel and benchtop next-generation sequencer can identify mutations and potentially actionable targets in the majority of GBM patients. Data from this pilot highlights the potential for targeted genetic resequencing to identify mutations that may inform treatment options and predict outcomes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
UNLABELLED: Glioblastoma (GBM) is a highly aggressive malignancy and the most effective treatment regime has a high relapse rate. Increasingly, the development of therapies involves defining drug-diagnostic combinations where the presence of a molecular target or marker identifies patients who are most likely to respond to a specific therapy. Trials in other solid cancers have demonstrated clear utility in the incorporation of biomarkers to stratify patients to targeted treatment, however, there are no mutations that are currently used to inform treatment options for GBM. AIMS: We piloted the use of high-throughput next-generation sequencing technology to identify genetic mutations in 44 GBM specimens that may be amenable to current or future targeted therapeutic strategies. METHOD: Somatic mutation profiling was performed using the AmpliSeq Cancer Hotspot Panel v2 and semiconductor sequencing technology. RESULTS: A total of 66 mutations were detected in 35/44 (80%) patients. The number of mutations per tumour ranged from 0 to 4 (average per tumour=1.5). The most frequent mutations were in TP53 (n=12), PTEN (n=9), EGFR (n=8) and PIK3CA (n=5). Clinically actionable somatic mutations were detected in 24/35 (69%) patients. CONCLUSIONS: This study demonstrates that the use of an 'off-the-shelf' oncogene primer panel and benchtop next-generation sequencer can identify mutations and potentially actionable targets in the majority of GBM patients. Data from this pilot highlights the potential for targeted genetic resequencing to identify mutations that may inform treatment options and predict outcomes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Belinda B Guo; Richard J Allcock; Bob Mirzai; Jacques A Malherbe; Fizzah A Choudry; Mattia Frontini; Hun Chuah; James Liang; Simon E Kavanagh; Rebecca Howman; Willem H Ouwehand; Kathryn A Fuller; Wendy N Erber Journal: Am J Pathol Date: 2017-05-11 Impact factor: 4.307
Authors: Wafik S El-Deiry; Richard M Goldberg; Heinz-Josef Lenz; Anthony F Shields; Geoffrey T Gibney; Antoinette R Tan; Jubilee Brown; Burton Eisenberg; Elisabeth I Heath; Surasak Phuphanich; Edward Kim; Andrew J Brenner; John L Marshall Journal: CA Cancer J Clin Date: 2019-05-22 Impact factor: 508.702
Authors: Sara A Byron; Nhan L Tran; Rebecca F Halperin; Joanna J Phillips; John G Kuhn; John F de Groot; Howard Colman; Keith L Ligon; Patrick Y Wen; Timothy F Cloughesy; Ingo K Mellinghoff; Nicholas A Butowski; Jennie W Taylor; Jennifer L Clarke; Susan M Chang; Mitchel S Berger; Annette M Molinaro; Gerald M Maggiora; Sen Peng; Sara Nasser; Winnie S Liang; Jeffrey M Trent; Michael E Berens; John D Carpten; David W Craig; Michael D Prados Journal: Clin Cancer Res Date: 2017-10-26 Impact factor: 12.531
Authors: Rick Kamps; Rita D Brandão; Bianca J van den Bosch; Aimee D C Paulussen; Sofia Xanthoulea; Marinus J Blok; Andrea Romano Journal: Int J Mol Sci Date: 2017-01-31 Impact factor: 5.923
Authors: Lorea Manterola; Pablo Aguirre; Erika Larrea; María Arestín; Ayman Gaafar; Kepa Elorriaga; Ibai Goicoechea; María Armesto; Marta Fernández-Mercado; Ignacio Zabalza; Juan Carlos López-Duque; Ekhiñe Larruskain; Jon Alexander Sistiaga; Mikel Landa; Aitor Zabala; Francisco Santaolalla; José Antonio Municio; Ángel Ispizua; Juana María García-Pedrero; Juan Pablo Rodrigo; Charles Henderson Lawrie Journal: Sci Rep Date: 2018-04-26 Impact factor: 4.379
Authors: Akanksha S Mahajan; Bruna M Sugita; Anju N Duttargi; Francisco Saenz; Ewa Krawczyk; Justine N McCutcheon; Aline S Fonseca; Bhaskar Kallakury; Paula Pohlmann; Yuriy Gusev; Luciane R Cavalli Journal: PLoS One Date: 2017-10-19 Impact factor: 3.240
Authors: H P Ellis; C E McInerney; D Schrimpf; F Sahm; A Stupnikov; M Wadsley; C Wragg; P White; K M Prise; D G McArt; K M Kurian Journal: J Oncol Date: 2019-12-31 Impact factor: 4.375